Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 2/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.45 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.45 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8229904 | 0.90 | GABRG2 (0.51) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL8422800 | 0.89 | GABRG2 (0.51) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL8422802 | 0.85 | GABRG2 (0.51) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL17088096 | 0.80 | GABRG2 (0.68) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL8238520 | 0.80 | GABRG2 (0.48) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL7306607 | 0.80 | GABRA1 (0.57) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL8235857 | 0.77 | GABRG2 (0.46) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL7318749 | 0.75 | GABRG2 (0.53) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL8229907 | 0.75 | GABRG2 (0.48) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL7306369 | 0.74 | GABRA1 (0.49) | GABRG2GABRB3GABRA5GABRA1GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060258643-A1 | GABAERGIC AGENTS TO TREAT MEMORY DEFICITS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258643-A1 | GABAERGIC AGENTS TO TREAT MEMORY DEFICITS | GABRA5, GABRA6, GABRA1 | GABRG2 16/4885GABRB3 10/4885GABRA5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.